Lupus Trial, Recruiting (NCT07397728)

Lupus Trial, Recruiting NCT07397728 Sponsor: South Valley University Condition: Lupus

Printed from Voxsanity (voxsanity.com.au) — NCT07397728 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lupus

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults between 18 and 60 years of age
People who have been diagnosed with Systemic Lupus Erythematosus (SLE) according to a specific set of medical guidelines from 2019 (known as the EULAR/ACR classification criteria)
People who have at least one skin-related symptom or rash associated with their condition (this can be a recent, ongoing, or long-term skin issue)
People who are willing to sign a consent form agreeing to take part in the study, including agreeing to genetic testing

Who may not be able to join:

People who have been diagnosed with another autoimmune condition alongside their lupus, such as dermatomyositis (a muscle and skin disease) or systemic sclerosis (a connective tissue disease)
People who currently have a serious infection, a cancer diagnosis, or who are pregnant
People who have used certain strong medications — specifically biologic therapies or high-dose immunosuppressive treatments — within the past month

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Eisa Mohammed Hegazy, Professor, Dermatology, Venereology and Andrology. Faculty of Medicine,Qena University

Phone: +201146299296

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07397728

Sponsor: South Valley University

Phase: Not Applicable

Status: Recruiting

Condition: Lupus

Trial contact: +201146299296

More information: https://clinicaltrials.gov/study/NCT07397728

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults between 18 and 60 years of age
People who have been diagnosed with Systemic Lupus Erythematosus (SLE) according to a specific set of medical guidelines from 2019 (known as the EULAR/ACR classification criteria)
People who have at least one skin-related symptom or rash associated with their condition (this can be a recent, ongoing, or long-term skin issue)
People who are willing to sign a consent form agreeing to take part in the study, including agreeing to genetic testing

Who may not be able to join:

People who have been diagnosed with another autoimmune condition alongside their lupus, such as dermatomyositis (a muscle and skin disease) or systemic sclerosis (a connective tissue disease)
People who currently have a serious infection, a cancer diagnosis, or who are pregnant
People who have used certain strong medications — specifically biologic therapies or high-dose immunosuppressive treatments — within the past month

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

South Valley University

Registry

ClinicalTrials.gov

Start date

10 June 2025

Est. completion

1 June 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Systemic Lupus Erythematosus Assessment; TREX1 gene polymorphism and SLE

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov